EGFR and esophageal squamous cell carcinoma: Treatment with TKIs, such as gefitinib and lapatinib, has been shown in vitro and in vivo to inhibit downstream effector pathway and proliferation of EGFR- and/or HER2-overexpressing ESCC [47,48].